Determination of Metabolic Rates and Enzyme Kinetics

Drug Metabolism in Drug Design and Development: Basic Concepts and Practice

Volumn , Issue , 2007, Pages 411-446

  Zhang, Zhi Yi ^a   Kaminsky, Laurence S ^b  

^a Eisal Research Institute   (United States)

^b WADSWORTH CENTER   (United States)

Author keywords

Drug metabolizing enzymes; Enzyme reaction phenotyping; Triple quadrupole mass spectrometer

Indexed keywords

EID: 84889402901     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470191699.ch13     Document Type: Chapter

References (85)

1. Ackley DC, Rockich KT, Baker TR. Metabolic stability assessed by liver microsomes and hepatocytes. In: Yan Z, Caldwell GW editors. Methods in Pharmacology and Toxicology: Optimization in Drug Discovery: In Vitro Method. Totowa, NJ: Human Press Inc; 2004; p151-162.
2. Adediran SA. Kinetic properties of normal human erythrocyte glucose-6-phosphate dehydrogenase dimmers. Biochimie 1991;73:1211-1218.
3. Andersson TB, Bredberg E, Ericsson H, Sjoberg H. An evaluation of the in vitro metabolism data for predicting the clearance and drug-drug interaction potential of CYP2C9 substrates. Drug Metab Dispos 2004;32:715-721.
4. Andersson TB, Sjoberg H, Hoffmann KJ, Boobis AR, Watts P, Edwards RJ, Lake BG, Price RJ, Renwick AB, Gomez-Lechon MJ, Castell JV, Ingelman-Sundberg M, Hidestrand M, Goldfarb PS, Lewis DF, Corcos L, Guillouzo A, Taavitsainen P, Pelkonen O. An assessment of human liver-derived in vitro systems to predict the in vivo metabolism and clearance of almokalant. Drug Metab Dispos 2001;29:712-720.
5. Apic G, Ignjatovic T, Boyer S, Russell RB. Illuminating drug discovery with biological pathways. FEBS Lett 2005;579:1872-1877.
6. Bargetzi MJ, Aoyama T, Gonzalez FJ, Meyer UA. Lidocaine metabolism in human liver microsomes by cytochrome P450IIIA4. Clin Pharmacol Ther 1989;46:521-527.
7. Bass L, Robinson P, Bracken AJ. Hepatic elimination of flowing substrates: the distributed model. J Theor Biol 1978;72:161-184.
8. Bayliss MK, Bell JA, Jenner WN, Wilson K. Prediction of intrinsic clearance of loxtidine from kinetic studies in rat, dog and human hepatocytes. Biochem Soc Trans 1990;18:1198-1199.
9. Broly F, Libersa C, Lhermitte M. Mexiletine metabolism in vitro by human liver. Drug Metab Dispos 1990;18:362-368.
10. Busby Jr WF, Ackermann JR, Crespi CL. Effect of methanol, ethanol, dimethyl sulfoxide, and acetonitrile on in vitro activities of cDNA-expressed human cytochromes P-450. Drug Metab Dispos 1999;27:246-249.
11. Campbell ME, Grant DM, Inaba T, Kalow W. Biotransformation of caffeine, paraxanthine, theophylline, and theobromine by polycyclic aromatic hydrocarboninducible cytochrome(s) P-450 in human liver microsomes. Drug Metab Dispos 1987;15:237-249.
12. Chauret N, Gauthier A, Nicoll-Griffith DA. Effect of common organic solvents on in vitro cytochrome P450-mediated metabolic activities in human liver microsomes. Drug Metab Dispos 1998;1:1-4.
13. Crespi CL, Stresser DM. Fluorometric screening for metabolism-based drug-drug interactions. J Pharmacol Toxicol Methods 2000;44:325-331.
14. Davies B, Morris T. Physiological parameters in laboratory animals and humans. Pharm Res 1993;10:1093-1095.
15. Dordal A, Lipkin M, Macritchie J, Mas J, Port A, Rose S, Salgado L, Savic V, Schmidt W, Serafini MT, Spearing W, Torrens A, Yeste S. A preliminary study of the metabolic stability of a series of benzoxazinone derivatives as potent neuropeptide Y5 antagonists. Bioorg Med Chem Lett 2005;15:3679-3684.
16. Easterbrook J, Lu C, Sakai Y, Li AP. Effects of organic solvents on the activities of cytochrome P450 isoforms, UDP-dependent glucuronyl transferase, and phenol sulfotransferase in human hepatocytes. Drug Metab Dispos 2001;29:141-144.
17. Fasco MJ, Piper LJ, Kaminsky LS. Biochemical applications of a quantitative highpressure liquid chromatographic assay of warfarin and its metabolites. J Chromatogr 1977;131:365-373.
18. Grant MH, Burke MD, Hawksworth GM, Duthie SJ, Engeset J, Petrie JC. Human adult hepatocytes in primary monolayer culture. Maintenance of mixed function oxidase and conjugation pathways of drug metabolism. Biochem Pharmacol 1987; 36:2311-2316.
19. Guengerich FP. Common and uncommon cytochrome P450 reactions related to metabolism and chemical toxicity. Chem Res Toxicol 2001;14:611-650.
20. Hakala KS, Suchanova B, Luukkanen L, Ketola RA, Finel M, Kostiainen R. Rapid simultaneous determination of metabolic clearance of multiple compounds catalyzed in vitro by recombinant human UDP-glucuronosyltransferases. Anal Biochem 2005;341:105-112.
21. Hewawasam P, Erway M, Moon SL, Knipe J, Weiner H, Boissard CG, Post-Munson DJ, Gao Q, Huang S, Gribkoff VK, Meanwell NA. Synthesis and structure-activity relationships of 3-aryloxindoles: a new class of calcium-dependent, large conductance potassium (maxi-K) channel openers with neuroprotective properties. J Med Chem 2002;45:1487-1499.
22. Hickman D, Wang JP, Wang Y, Unadkat JD. Evaluation of the selectivity of in vitro probes and suitability of organic solvents for the measurement of human cytochrome P450 monooxygenase activities. Drug Metab Dispos 1998;3:207-215.
23. Holleran JL, Egorin MJ, Zuhowski EG, Parise RA, Musser SM, Pan SS. Use of highperformance liquid chromatography to characterize the rapid decomposition of wortmannin in tissue culture media. Anal Biochem 2003;323:19-25.
24. Houston JB, Galetin A. Progress towards prediction of human pharmacokinetic parameters from in vitro technologies. Drug Metab Rev 2003;35:393-415.
25. Ito K, Houston JB. Comparison of the use of liver models for predicting drug clearance using in vitro kinetic data from hepatic microsomes and isolated hepatocytes. Pharm Res 2004;21:785-792.
26. Ito K, Houston JB. Prediction of human drug clearance from in vitro and preclinical data using physiologically based and empirical approaches. Pharm Res 2005;22:103-112.
27. Iwatsubo T, Hirota N, Ooie T, Suzuki H, Shimada N, Chiba K, Ishizaki T, Green CE, Tyson CA, Sugiyama Y. Prediction of in vivo drug metabolism in the human liver from in vitro metabolism data. Pharmacol Ther 1997;73:147-171.
28. Jenkins KM, Angeles R, Quintos MT, Xu R, Kassel DB, Rourick RA. Automated high throughput ADME assays for metabolic stability and cytochrome P450 inhibition profiling of combinatorial libraries. J Pharm Biomed Anal 2004;34:989-1004.
29. Kalvass JC, Tess DA, Giragossian C, Linhares MC, Maurer TS. Influence of microsomal concentration on apparent intrinsic clearance: implications for scaling in vitro data. Drug Metab Dispos 2001;29:1332-1336.
30. Kroemer HK, Echizen H, Heidemann H, Eichelbaum M. Predictability of the in vivo metabolism of verapamil from in vitro data: contribution of individual metabolic pathways and stereoselective aspects. J Pharmacol Exp Ther 1992;260:1052-1057.
31. Krueger SK, Williams DE. Mammalian flavin-containing monooxygenases: structure/ function, genetic polymorphisms and role in drug metabolism. Pharmacol Ther 2005;106:357-387.
32. Lai F, Khojasteh-Bakht SC. Automated online liquid chromatographic/mass spectrometric metabolic study for prodrug stability. J Chromatogr B Analyt Technol Biomed Life Sci 2005;814:225-232.
33. Levine B, Zhang X, Smialek JE, Kunsman GW, Frontz ME. Citalopram distribution in postmortem cases. J Anal Toxicol 2001;25:641-644.
34. Li AP, Rasmussen A, Xu L, Kaminski DL. Rifampicin induction of lidocaine metabolism in cultured human hepatocytes. J Pharmacol Exp Ther 274:1995;673-677.
35. Li XQ, Bjorkman A, Andersson TB, Gustafsson LL, Masimirembwa CM. Identification of human cytochrome P(450)s that metabolise anti-parasitic drugs and predictions of in vivo drug hepatic clearance from in vitro data. Eur J Clin Pharmacol 2003;59:429-442.
36. Liederer BM, Borchardt RT. Stability of oxymethyl-modified coumarinic acid cyclic prodrugs of diastereomeric opioid peptides in biological media from various animal species including human. J Pharm Sci 2005;94:2198-2206.
37. Lin JH, Lu AY. Role of pharmacokinetics and metabolism in drug discovery and development. Pharmacol Rev 1997;49:403-449.
38. Lin Y, Lu P, Tang C, Mei Q, Sandig G, Rodrigues AD, Rushmore TH, Shou M. Substrate inhibition kinetics for cytochrome P450-catalyzed reactions. Drug Metab Dispos 2001;29:368-374.
39. MacKenzie AR, Marchington AP, Middleton DS, Newman SD, Jones BC. Structureactivity relationships of 1-alkyl-5-(3,4-dichlorophenyl)- 5-[2-[(3-substituted)-1-azetidinyl] ethyl]-2-piperidones. 1. Selective antagonists of the neurokinin-2 receptor. J Med Chem 2002;45:5365-5377.
40. Mandagere AK, Thompson TN, Hwang KK. Graphical model for estimating oral bioavailability of drugs in humans and other species from their Caco-2 permeability and in vitro liver enzyme metabolic stability rates. J Med Chem 2002;45:304-311.
41. Masimirembwa CM, Bredberg U, Andersson TB. Metabolic stability for drug discovery and development: pharmacokinetic and biochemical challenges. Clin Pharmacokinet 2003;42:515-528.
42. Mei Q, Tang C, Lin Y, Rushmore TH. Shou M. Inhibition kinetics of monoclonal antibodies against cytochromes P450. Drug Metab Dispos 2002;30:701-708.
43. Nakajima M, Tanaka E, Kwon JT, Yokoi T. Characterization of nicotine and cotinine N-glucuronidations in human liver microsomes. Drug Metab Dispos 2002;30:1484-1490.
44. Naritomi Y, Terashita S, Kimura S, Suzuki A, Kagayama A, Sugiyama Y. Prediction of human hepatic clearance from in vivo animal experiments and in vitro metabolic studies with liver microsomes from animals and humans. Drug Metab Dispos 2001;29:1316-1324.
45. Naritomi Y, Terashita S, Kagayama A, Sugiyama Y. Utility of hepatocytes in predicting drug metabolism: comparison of hepatic intrinsic clearance in rats and humans in vivo and in vitro. Drug Metab Dispos 2003;31:580-588.
46. Nnane IP, Damani LA. Involvement of cytochrome P450 and the flavin-containing monooxygenase(s) in the sulphoxidation of simple sulphides in human liver microsomes. Life Sci 2003;73:359-369.
47. Obach RS. Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: An examination of in vitro half-life approach and nonspecific binding to microsomes. Drug Metab Dispos 1999;11:1350-1359.
48. Obach RS. Metabolism of ezlopitant, a nonpeptidic substance P receptor antagonist, in liver microsomes: enzyme kinetics, cytochrome P450 isoform identity, and in vitro-in vivo correlation. Drug Metab Dispos 2000;28:1069-1076.
49. Obach RS. The prediction of human clearance from hepatic microsomal metabolism data. Curr Opin Drug Discov Devel 2001;4:36-44.
50. Obach RS, Baxter JG, Liston TE, Silber BM, Jones BC, MacIntyre F, Rance DJ, Wastall P. The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data. J Pharmacol Exp Ther 1997;283:46-58.
51. Obach RS, Reed-Hagen AE. Measurement of Michaelis constants for cytochrome P450-mediated biotransformation reactions using a substrate depletion approach. Drug Metab Dispos 2002;30:831-837.
52. Pang KS, Rowland M. Hepatic clearance of drugs. I. Theoretical considerations of a ''well-stirred'' model and a ''parallel tube'' model. Influence of hepatic blood flow, plasma and blood cell binding, and the hepatocellular enzymatic activity on hepatic drug clearance. J Pharmacokinet Biopharm 1977a;5:625-653.
53. Pang KS, Rowland M. Hepatic clearance of drugs. II. Experimental evidence for acceptance of the ''well-stirred'' model over the ''parallel tube''model using lidocaine in the perfused rat liver in situ preparation. J Pharmacokinet Biopharm 1977b;5:655-680.
54. Raucy JL, Lasker JM. Isolation of P450 enzymes from human liver. Methods Enzymol 1991;206:577-587.
55. Reddy A, Heimbach T, Freiwald S, Smith D, Winters R, Michael S, Surendran N, Cai H. Validation of a semi-automated human hepatocyte assay for the determination and prediction of intrinsic clearance in discovery. J Pharm Biomed Anal 2005;37:319-326.
56. Richard B, Fabre G, De Sousa G, Fabre I, Rahmani R, Cano JP. Interspecies variability in mitoxantrone metabolism using primary cultures of hepatocytes isolated from rat, rabbit and humans. Biochem Pharmacol 1991;41:255-262.
57. Roberts MS, Rowland M. Correlation between in vitro microsomal enzyme activity and whole organ hepatic elimination kinetics: analysis with a dispersion model. J Pharm Pharmacol 1986a;38:177-181.
58. Roberts MS, Rowland M. A dispersion model of hepatic elimination: 2. Steady-state considerationsinfluence of hepatic blood flow, binding within blood, and hepatocellular enzyme activity. J Pharmacokinet Biopharm 1986b;14:261-288.
59. Roberts MS, Rowland M. A dispersion model of hepatic elimination: 3. Application to metabolite formation and elimination kinetics. J Pharmacokinet Biopharm 1986c;14: 289-308.
60. Rowland M, Benet LZ, Graham GG. Clearance concepts in pharmacokinetics. J Pharmacokinet Biopharm 1:1973;123-136.
61. Satoh T, Hosokawa M. The mammalian carboxylesterases: from molecules to functions. Annu Rev Pharmacol Toxicol 1998;38:257-288.
62. Satoh T, Taylor P, Bosron WF, Sanghani SP, Hosokawa M, La Du BN. Current progress on esterases: from molecular structure to function. Drug Metab Dispos 30:2002;488-493.
63. Seddon T, Michelle I, Chenery RJ. Comparative drug metabolism of diazepam in hepatocytes isolated from man, rat, monkey and dog. Biochem Pharmacol 1989;38:1657-1665.
64. Shen M, Xiao Y, Golbraikh A, Gombar VK, Tropsha A. Development and validation of k-nearest-neighbor QSPR models of metabolic stability of drug candidates. J Med Chem 2003;46:3013-3020.
65. Shibata Y, Takahashi H, Ishii Y. A convenient in vitro screening method for predicting in vivo drug metabolic clearance using isolated hepatocytes suspended in serum. Drug Metab Dispos 2000;28:1518-1523.
66. Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 1994;270:414-423.
67. Shou M, Lin Y, Lu P, Tang C, Mei Q, Cui D, Tang W, Ngui JS, Lin CC, Singh R, Wong BK, Yergey JA, Lin JH, Pearson PG, Baillie TA, Rodrigues AD, Rushmore TH. Enzyme kinetics of cytochrome P450-mediated reactions. Curr Drug Metab 2001;2:17-36.
68. Skopp G, Klingmann A, Potsch L, Mattern R. In vitro stability of cocaine in whole blood and plasma including ecgonine as a target analyte. Ther Drug Monit 2001;23:174-181.
69. Slaughter D, Takenaga N, Lu P, Assang C, Walsh DJ, Arison BH, Cui D, Halpin RA, Geer LA, Vyas KP, Baillie TA. Metabolism of rofecoxib in vitro using human liver subcellular fractions. Drug Metab Dispos 2003;31:1398-1408.
70. Smith DA, van de Waterbeemd H. Pharmacokinetics and metabolism in early drug discovery. Curr Opin Chem Biol 1999;3:373-378.
71. Smith RL, Timbrell JA. Factors affecting the metabolism of phenacetin. I. Influence of dose, chronic dosage, route of administration and species on the metabolism of (1-14C-acetyl)phenacetin. Xenobiotica 1974;4:489-501.
72. Soars MG, Burchell B, Riley RJ. In vitro analysis of human drug glucuronidation and prediction of in vivo metabolic clearance. J Pharmacol Exp Ther 2002;301:382-390.
73. Sugie M, Asakura E, Zhao YL, Torita S, Nadai M, Baba K, Kitaichi K, Takagi K, Takagi K, Hasegawa T. Possible involvement of the drug transporters P-glycoprotein and multidrug resistance-associated protein Mrp2 in disposition of azithromycin. Antimicrob Agents Chemother 2004;48:809-814.
74. Takahashi H, Kashima T, Kimura S, Muramoto N, Nakahata H, Kubo S, Shimoyama Y, Kajiwara M, Echizen H. Determination of unbound warfarin enantiomers in human plasma and 7-hydroxywarfarin in human urine by chiral stationary-phase liquid chromatography with ultraviolet or fluorescence and on-line circular dichroism detection. J Chromatogr B Biomed Sci Appl 1997;701:71-80.
75. Tang C, Shou M, Rushmore TH, Mei Q, Sandhu P, Woolf EJ, Rose MJ, Gelmann A, Greenberg HE, De Lepeleire I, Van Hecken A, De Schepper PJ, Ebel DL, Schwartz JI, Rodrigues AD. In vitro metabolism of celecoxib, a cyclooxygenase-2 inhibitor, by allelic variant forms of human liver microsomal cytochrome P450 2C9: correlation with CYP2C9 genotype and in vivo pharmacokinetics. Pharmacogenetics 2001;11: 223-235.
76. Tracy TS. Atypical enzyme kinetics: their effect on in vitro-in vivo pharmacokinetic predictions and drug interactions. Curr Drug Metab 2003;4:341-346.
77. Wilkinson GR, Shand DG. Commentary: a physiological approach to hepatic drug clearance. Clin Pharmacol Ther 1975;18:377-390.
78. Winkler K, Keiding S, Tygstrup N. The liver. In: Paumgartner G, Preisig R. editors. Quantitative Aspects of Structure and Function. Basel: S Karger; 1973. p 144-155.
79. Yamamoto T, Hagima N, Nakamura M, Kohno Y, Nagata K, Yamazoe Y. Differences in cytochrome P450 forms involved in the metabolism of N,N-dipropyl-2-[4-methoxy-3-(2-phenylethoxy)phenyl]ethylamine monohydrochloride (NE-100), a novel sigma ligand, in human liver and intestine. Drug Metab Dispos 2003;31:60-66.
80. Zhang ZY, Kaminsky LS. Characterization of human cytochromes P450 involved in theophylline 8-hydroxylation. Biochem Pharmacol 1995;50:205-211.
81. Zhang ZY, King BM, Mollova NN, Wong YN. In vitro interactions between a potential muscle relaxant E2101 and human cytochromes P450. Drug Metab Dispos 2002;30:805-813.
82. Zhang ZY, Wong YN. Enzyme kinetics for clinically relevant CYP inhibition. Curr Drug Metab 2005;6:241-257.
83. Zhao SX, Forman D, Wallace N, Smith BJ, Meyer D, Kazolias D, Gao F, Soglia J, Cole M, Nettleton D. Simple strategies for reducing sample loads in in vitro metabolic stability high-throughput screening experiments: a comparison between traditional, two-time-point and pooled sample analyses. J Pharm Sci 2005;94:38-45.
84. Ziegler DM. An overview of the mechanism, substrate specificities, and structure of FMOs. Drug Metab Rev 2002;34:503-511.
85. Zuegge J, Schneider G, Coassolo P, Lave T. Prediction of hepatic metabolic clearance: comparison and assessment of prediction models. Clin Pharmacokinet 2001;40:553-563.